Brian D. Vaillant, MD

Board-Certified Neuro-Oncologist


Brian D. Vaillaint, MD, is a board-certified neuro-oncologist.

What I Love About My Job

“I’m pleased to provide comprehensive neuro-oncology care with a wide array of state-of-the-art treatments. Each person is unique, and I strive to tailor the treatment plan to each individual while helping my patients and their families navigate through a difficult time.”


To schedule an appointment with Dr. Brian D. Vaillant, call Austin Cancer Center at 512.505.5500 today, or use our online Request an Appointment form.

Educational Background

Dr. Vaillant earned his undergraduate degree as well as his medical degree from the University of Wisconsin-Madison. He fulfilled his residency in neurology at the University of Washington Medical Center in Seattle and completed both a neuro-oncology fellowship and research fellowship at MD Anderson Cancer Center in Houston, Texas.

Awards & Research

Dr. Vaillant specializes in the care of patients with brain and spinal tumors (both primary and metastatic) as well as patients with neurological complications due to cancer. He has a special interest in glioma stem cell research and translational research. Dr. Vaillant serves as the Director of Neuro-Oncology for Austin Cancer Center.

Dr. Vaillant is licensed in Texas, and he is a diplomat with the American Board of Psychiatry and Neurology.


A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients (Read)

Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting (Read)

Regulation of HGF expression by ?EGFR-mediated c-Met activation in glioblastoma cells  (Read)

Mesenchymal differentiation mediated by NF-?B promotes radiation resistance in glioblastoma (Read)

Experimental validation of 5 in-silico predicted glioma biomarkers (Read)

ELTD1, A Potential New Biomarker for Gliomas (Read)

A prognostic gene expression signature in infratentorial ependymoma (Read)

The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma (Read)

Treatment of spinal cord tumors (Read)

Emerging subspecialties in neurology: neuro-oncology: a developing subspecialty with many opportunities (Read)

Antineutrophil cytoplasmic antibody-associated active scleritis (Read)

Expression of matrix metalloproteinases and their inhibitors during the resorption of schistosome egg-induced fibrosis in praziquantel-treated mice (Read)

The cloning by complementation of the pawn-A gene in Paramecium (Read)

PAK Paradox: Paramecium Appears To Have More K+-Channel Genes than Humans (Read)

Random mutagenesis reveals a region important for gating of the yeast K+ channel Ykc1 (Read)